Featured Articles
Featured
The prevalence of keratoconus was found to be 1 in 100 children (1.0%) in a new expert re-analysis of pediatric data co-authored by Epion’s Chief Medical Officer, Michael W. Belin, MD.
In their latest newsletter, the National Keratoconus Foundation (NKCF), highlights Epion Therapeutics’ Phase 3 trials of the EpiSmart Epithelium-On Cross-Linking System.
Keratoconus is a progressive disease with significant visual and quality of life implications. CXL can slow progression of the disease in a very high proportion of patients. Safe and effective CXL treatment predicates the importance of early disease diagnosis.
Jennifer Harthan, OD, FAAO, FSLS, shared the importance of early diagnostics and pediatric screening of keratoconus at the IKA 2024 Symposium.
The number of keratoconus treatment options is growing, with new techniques and devices in development.
Chief Medical Officer Michael W. Belin provides updates on Epion’s investigational epithelium-on cross-linking technology in this special edition of EyewireTV.
Review of Ophthalmology looks at what’s coming to cross-linking, both in and out of the FDA pipeline.